TrialESMO open2022

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF

J Tabernero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.